NCT00532454

Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen

A Clinical Study for the Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen in Patients With Metastatic Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Primary objectives of this study is to evaluate the effects of CYP2D6 genotypes on time to progression after tamoxifen treatment in pre- or postmenopausal women with metastatic breast cancer. Furthermore, we will evaluate the effects of CYP2D6 genotypes on clinical benefit and response duration to tamoxifen administration in pre- or postmenopausal women with metastatic breast cancer and also evaluate the effects of CYP2D6 genotypes on the steady state plasma concentration of tamoxifen and its metabolites

Conditions

• Breast Cancer
• Metastatic Disease

Interventions

Type	Name	Description
DRUG	Tamoxifen	tamoxifen 20mg, PO, QD until disease progression

Timeline

• Start date: 2006-06-01
• Primary completion: 2006-06-01
• Completion: 2007-12-01
• First posted: 2007-09-20
• Last updated: 2010-02-10

Locations

2 sites across 1 country: South Korea